Summary Polyethylene glycol (PEG) modification of a chimeric Fab' fragment (F9) of A5B7 (a-CEA), using an improved coupling method, increases its specificity for subcutaneous LS174T tumours. PEGylation increased the area under the concentration-time curve (AUCo-144) in all tissues but there were significant differences (variance ratio test, F=27.95, P<0.001) between the proportional increases in AUCo144, with the tumour showing the greatest increase. The increase in AUCtumour from F9 to PEG-F9 was similar to the reported increase from Fab' to F(ab')2 while the increase in AUCbl..d by PEGylation of F9 was only 21% of the reported increase from Fab' to whole IgG. A two sample t-test showed no significant differences between maximal tumour/tissue ratios for PEG-F9 and F9 while the tumour/tissue ratios for PEG-F9 remained high over a longer period, with tumour levels at least double those for F9. PEG-F9 emerges as a new generation antibody with potential advantages for both radioimmunotherapy and tumour imaging. Since there was a reduction in antigen binding, optimisation of PEGylation might further improve tumour specificity. The latter resulted from complex effects on both the entry into and exit rates from tumour and normal tissues in a tissuespecific fashion.
Covalent modification of proteins with poly(ethylene glycol)(PEG) has emerged as the method of choice to overcome the major problems associated with protein therapeutics Delgado et al., 1992a) . Increased plasma half-life, increased resistance to proteolysis and substantial reduction in antigenicity/immunogenicity have been found in almost all recombinant and native proteins after PEGylation. The success of this technology is indicated by the number of PEG proteins already in clinical trials .
The benefits of PEG-modification might also extend beyond these recognised advantages, since PEG-coupled antibodies (Kitamura et al., 1990 (Kitamura et al., , 1991 and PEG-coupled liposomes (Martin et al., 1991) have recently been reported to have tumour-localising properties. The mechanisms leading to the improved localisation are, however, unclear. Whether the observed tumour-localising effect simply resulted from the longer circulation time or was related to some other consequence of PEGylation remains to be established. PEG changes the surface properties of the molecules and macromolecular structures to which it is attached ; short range charge-based interactions are precluded and there is a relationship between the extent to which this occurs and the length of the PEG (Yoshioka, 1991) . In addition, PEG alters the solubility of molecules and this might influence the capacity of PEG constructs to cross the extracellular matrix and other structures, hence entry to and exit from different sites.
We have developed an improved method (Francis et al., 1995a) for the attachment of PEG to proteins based on an earlier method that uses activation of the polymer with tresyl chloride (Delgado et al., 1990) . The tresylated PEG (TMPEG) has many advantages over PEGs activated by other methods Francis et al., 1991; Malik et al., 1992) . It links PEG to proteins using mild conditions for the coupling step, which results in a better conservation of biological activity; the activated polymer shows low toxicity, which allows addition of the whole reaction mixture to biological assay systems for a rapid test of the bioactivity of the PEG-protein conjugates (Fisher et al., 1995; Francis et al., 1995b) . The PEG is attached directly to the molecule via a stable secondary amine linkage without any coupling moiety (portion of the activated PEG molecule remaining in the PEG-protein construct). The latter is particularly undesirable since coupling moieties can react linking further molecules, or be immunogenic/antigenic, are sometimes toxic and potentially cleaved enzymatically. The surface properties of the conjugate might also be affected by a coupling moiety (by altering the charge and/or the hydrophobicity/hydrophilicity balance). Our improved coupling method thus provides a unique tool with which to study the influence of PEGylation per se in tumour localisation.
We have PEG-modified a recombinant chimeric F(ab') fragment (F9) with variable regions derived from A5B7 (a murine monoclonal antibody to human carcinoembryonic antigen) and human CHI (gamma isotype) and C kappa constant regions using TMPEG. PEG-F9 has been used to investigate the effects of PEG-modification on tumour localisation using a colonic tumour xenograft, LS174T, grown in TO nude mice.
Materials and methods
Chemicals were obtained from: MPEG (Mr 5000, Union Carbide, USA), PEG (Mr 6000, BDH, Poole, UK), dextran T-500 (Pharmacia, Sweden), tresyl chloride (Fluka, Switzerland). Phosphate-buffered saline (PBS) was from Gibco or Sigma (Poole, UK) and '25I from Amersham (UK). Molecular weight markers were from Sigma. A kit for protein determination using the Coomassie brilliant blue assay was from Pierce (Rockford, IL, USA). All other reagents were Analar grade from BDH (Poole, UK). Calculation of the AUCo ,44 was done by the linear trapezoid method using the mean tissue concentrations (y) at each time point (t). The following expression described by Yuan (1993) was used:
AUCto-tn = 1/2(t -to) )o + E 1/2(4 -ti-2)9-1+ 1/2(tn-tn-l)Yn This expression shows that the estimated AUCtO , is a linear combination of mean concentrations at each time point (Yuan, 1993) and therefore the variance (s.d.2) of the AUCto, estimate can be calculated from the estimated standard error (s.e.m.) of the mean tissue concentrations at each time point using the expression described by Yuan (1993) :
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Statistical analysis
The increments in AUCO 144 promoted by PEGylation were compared using the F-test for the variance ratio. The maximal tumour to tissue ratios for F9 and PEG-F9 in each organ were compared using a two (unpaired) sample t-test.
Binding studies
Flat-bottomed microtitre plates receiving CEA in PBS (0.2 ,g per well) were incubated for 1 h at room temperature. Wells were then washed with PBS and quenched with 3% BSA in PBS (150 pl per well) for ca 2 h at room temperature. Wells were washed twice with PBS before receiving the sample containing F9 or PEG-F9. Incubation was carried out overnight at room temperature and after washing three times with PBS containing 0.05% Tween 20 and four times with distilled water, the 1251 content in each well was measured in a gamma counter. Neither F9 nor PEG-F9 showed any binding to PBS-coated wells.
Results
Incubation of F9 with TMPEG resulted in the formation of species with larger molecular sizes as shown by the appearance of faster eluting peaks in gel permeation chromatography (Figure 1 ). The proportion of larger molecular size species increased with the concentration of TMPEG in the reaction mixture, while the proportion of material eluting at the location of the unmodified F9 decreased (Figure 1 ). To confirm that the increase in molecular size was due to the formation of PEG-F9 conjugates, the reaction mixtures and sham-treated control (see methods) were analysed in a PEG/dextran two-phase system. The principle exploited here is that PEG-proteins have a higher affinity for the PEG-rich top phase than their unmodified counterparts (Delgado et al., 1990 . The partition coefficient (ratio between protein concentrations in top and bottom phases) of F9 in a 5% PEG-6000, 5% dextran T500, charge insensitive two-phase system was 1.14 + 0.08 (mean + s.e.m, n = 5). After incubation with TMPEG the partition coefficient increased to 4.01+0.42 (n = 3) for a reaction mixture containing TMPEG at a molar excess of 75:1 (TMPEG: free amino groups) and 6.42 + 1.23 (n = 3) when the molar excess of TMPEG was raised to 300:1. The increase in both molecular size and partition coefficient confirms the formation of PEG-F9 conjugates. The broadness of the FPLC profiles suggests that under all reaction consistent with an increase in the proportion of conjugates of higher degrees of substitution.
To test the influence of PEG modification on the tumour localisation of the antibody fragment, PEG-F9 conjugates were produced by incubation of F9 and TMPEG at a molar excess of TMPEG to NH2 of 300:1 ( Figure Id) . These reaction conditions were selected to minimise the contamination of the sample with unmodified F9 and to increase the proportion of species with molecular sizes exceeding the renal threshold.
The binding of PEG-F9 to the antigen was studied in comparison with that of F9 in order to establish how important this is for tumour localisation. Both untreated and control F9 (i.e. F9 exposed to 2 h incubation in PBS at room temperature) showed similar binding to the antigen which was greater than antigen binding for PEG-F9 (Figure 2 ). In this case, the reduced binding probably implies the presence of one or more lysines in, or near, the antigen-binding site. Reduction in receptor-binding affinity has previously been observed for proteins PEGylated by earlier TMPEG methods (Delgado et al., 1992b; Smith et al., 1991) . However, this previous method gave relatively good conservation of bioactivity Malik et al., 1992) , now further improved by the modified method (Francis et al., 1995a) . Figure 3 shows the blood clearance for F9 and PEG-F9 in TO nude mice bearing LS174T tumours. F9 was rapidly removed from the circulation and PEG-F9 showed the typical enhanced life in the circulation of PEG-modified proteins. Figure 4 compares the concentrations of F9 and PEG-F9 in LS174T tumours subcutaneously implanted in the flank. F9 and PEG-F9 profiles in the tumour tissue run almost in parallel, albeit with higher levels for PEG-F9 than for F9 at all time points (Figure 4, solid lines) of F9 per g of blood by 3 h post injection and by 10 h post injection tumour levels already exceeded blood levels ( Figure  4 ). For PEG-F9 tumour levels only exceeded blood levels at a later time point, between 10 and 24 h post injection ( Figure  4 ). It should be noted that for F9, tumour/blood ratios rise and then fall, whereas for PEG-F9 tumour/blood ratios increase progressively from 24 to 144 h (see below). Figure 5 shows the biodistribution of F9 and PEG-F9 to kidney, liver, spleen, lung, colon and muscle. In all tissues the levels of PEG-F9 were above the levels of F9 at virtually all time points although the proportional increase varied from tissue to tissue and also, in contrast to the tumour, with time post injection (i.e. biodistribution profiles for F9 and PEG-F9 do not run in parallel) ( Figure 5, solid lines) . The time beyond which tissue levels exceed blood levels was tissue 
specific and for all tissues longer for PEG-F9 than for F9 ( Figure 5 ) thus PEG modification altered the pharmacokinetics of F9 in a tissue-specific fashion (a mathematical analysis of these changes is given in the appendix). The tumour is the tissue receiving the greatest dose of PEG-F9 followed by kidney (Table I) . Liver, spleen, lung, colon and muscle received a much lower dose of PEG-F9, at least a third of the tumour dose (Table I) . With unmodified F9 the kidney received the greatest dose and although tumour received the second highest dose, it was ca five times smaller than that received by the kidney (Table I) . Liver, spleen and lung received similar doses of F9 and colon and muscle received lower doses (Table I) . PEGylation increased the dose delivered to all tissues (Table I) Enhanced tumour specfficity by PEGylation C Delgado et a! 180 tissues, excluding the kidney, tumour to tissue ratios increase sharply to reach a maximum at 24 h (lung, liver, spleen, colon and muscle) or 72 h (blood) followed by a marked decline ( Figure 6 ). The tumour to kidney ratios for F9 were below 1 at all time points and declined with time post injection ( Figure 6 ). For PEG-F9, the tumour to tissue ratios show the following patterns with time post injection: (1) increase (blood and lung); (2) increase and then decline (kidney, liver and muscle); and (3) increase to reach a plateau (spleen and colon). A two sample t-test showed no significant differences between the maximum ratio observed for PEG-F9 and F9 in any of the tissues studied. For blood and lung the tumour to tissue ratios increased over the time window of the study and therefore it is possible that the maximum ratio for PEG-F9 had not been achieved. In addition, the tumour to tissue ratios for liver, spleen and colon are maintained at high levels for a much longer period for PEG-F9 than for F9 ( Figure 6 ). In all tissues the highest tumour to tissue ratio for PEG-F9 is achieved at a tumour level at least twice that for F9 at maximal ratios.
Discussion
The F(ab') fragment of A5B7, F9 has been successfully PEGylated using TMPEG as the activated PEG. PEG-F9 shows the extended plasma half-life typical of PEGylated proteins. The increased plasma half-life is mainly a consequence of reduced renal clearance. High levels of F9 in the kidney at early time points suggest that F9 is rapidly cleared by the kidney, presumably by glomerular filtration, although some of the protein might be subjected to tubular reabsorption and metabolism; however, mouse urine in contrast to human urine contains high concentrations of protein due to relatively poor tubular reabsorption (Jacoby and Fox, 1984) . Rapid renal clearance of F9 is not surprising since, despite its molecular mass of 50 kDa (theoretical hydrodynamic radius 29.25 A), its apparent hydrodynamic radius is ca 22 A, as estimated by gel permeation chromatography on a Superose 12 column (see legend to Figure 1 ). It is well established that molecules with effective molecular radius below 20 A are freely filtered by the glomerular capillary wall (Rabkin and Dahl, 1993) . Molecules with sizes in the range 20-35 A are subjected to glomerular filtration and the extent to which its filtration is hindered by the glomerular barrier is directly related to its size and also depends on charge, shape and rigidity (Arendshorst and Navar, 1988) . The glomerular capillary wall almost completely restricts the passage of molecules of molecular radius greater then 35 A. PEG-F9 is a heterogeneous preparation with species sp,anning a range of apparent hydrodynamic radii from 29 A to > 40 A (as measured with the Superose 12 column). Thus some of the PEGi-F9 species are excluded by the glomerular barrier while others are filtered to some extent. Since a relatively high proportion of PEG-F9 is detected in the kidney, it is presumed that the filtered species are reabsorbed by the renal tubules (the presence of PEG might compromise catabolism since PEG proteins are relatively resistant to proteolysis, but this needs to be established).
The immediate consequence of the reduced renal clearance is increased plasma and tissue levels (i.e. increased AUC). There were statistical differences between the proportional increases in AUCO 144 due to PEGylation in the different tissues. The AUCO 144 increased proportionally more for the tumour than for the normal tissues and thus there is increased specificity for the tumour. The different proportional increases in AUCO ,. between the tissues might provide an additional unexpected benefit by increasing the effectivity of PEG-modified conjugates towards tumours located in tissues which exclude the PEG protein to a greater extent than the unmodified counterpart.
In order to establish any possible advantage of PEG-F9 over the antibody forms already in use in the clinic [whole IgG, F(ab')2 fragments] we have compared the effect of PEGylation on tumour localisation of F9 with that reported for other forms of A5B7, whole IgG, F(ab')2 and Fab' . For this purpose the AUC for tumour and blood were calculated between 3 and 144 h using the mean concentrations for 3 h, 24 h and 144 h, which were the only three time points used in both studies. The increase in AUC3 144 for the tumour following PEGylation of F9 was similar to the increase in AUC3144 from Fab' to F(ab')2. This was achieved with an increase in AUC3 -44 for blood by PEGylation of F9, which corresponds to only 21% of the increase in AUC3 144 from Fab' to whole IgG. provides a dose to the tumour similar to that provided by conventional F(ab')2 fragments, while keeping the dose to the blood (and hence to the bone marrow) well below that delivered by the whole IgG. These features, together with the generic benefits that PEGylation conveys to protein therapeutics Delgado et al., 1992a) , suggests that PEG-F9 might be superior to F(ab')2 fragments, currently the most promising agent in clinical trials (Bucheggar et al., 1990; Yorke et al., 1991; Pedley et al., 1993; Lane et al., 1994) , for radiommunotherapy.
PEGylation not only increased the total dose of F9 delivered to the tumour but also provided high tumour to tissue ratios (similar or greater for PEG-F9 than for F9) and over a longer period of time. In addition these improved tumour to tissue ratios are achieved with tumour levels at least twice those of F9 at maximal ratios in all tissues. Thus PEG-F9 should prove more powerful than F9 for both drug delivery and tumour imaging.
The binding of the fragment to the antigen was reduced after PEGylation, thus it is encouraging to have achieved an increase in tumour specificity, in the face of this loss. It should be noted that the coupling of PEG to the antibody can be optimised for maximum retention of antigen binding (for example, via PEGylation in the presence of antigen to mask the binding site). This might further improve the tumour specificity. However, the reduced antigen binding of PEG-F9 might have been beneficial. Although, at relatively high doses, antibody tumour uptake increases with its affinity for the antigen (Thomas et al., 1989) , it is well established that antigen-antibody interaction can retard antibody percolation beyond the tumour cells nearest to the capillaries, thus constituting a 'binding site barrier', which results in a more heterogeneous distribution (Fujimori et al., 1989) .
In order to gain insight into what changes to the rates of entry into and exit from the tissues were responsible for the increased tumour specificity, a two-compartment model that provides a numerical solution for these rates has been used (see appendix). PEGylation had a variety of effects on transit into and out of normal tissues and the tumour. Since these complex effects may relate to more than one property of PEG, optimisation of these encouraging early results will need systematic dissection of the impact of factors such as PEG chain length and degree of substitution on individual transfer rates. To that end, investigation of more direct measurements of tumour uptake and egress, using animal models such as those of Tozer et al. (1994) would be beneficial. In addition, development of improved mathematical modelling tools for the study of biodistribution would be useful. (Figure 7) , the mass balance for a substance in compartment 2 is given by the differential equation:
( 1) where q, and q2 are the concentrations of the substance in compartments 1 and 2 respectively.
Equation (1) can be re-written as:
If the substance is introduced at time zero into compartment 1, the concentration of the substance in compartment 2 at the generic time t, q2,, is obtained by integration of equation (2) Figure 8 shows the rates obtained for the unmodified F9 in comparison with those for PEG-F9. In all tissues except the liver, the KS, rate was decreased by PEGylation (Figure 8, top) . The K.. rates, decreased after PEGylation for tumour, muscle, colon and lung. In contrast, in liver, spleen and kidney PEG-F9 had greater values for K, than F9 (Figure 8, bottom) 
